Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $995

Benzinga Newsdesk www.benzinga.com Positive 80.6%

Neg 0% Neu 0% Pos 80.6%

Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $975 to $995.